Search Medical Condition
Please enter condition
Please choose location from dropdown

Saint-Quentin, France Clinical Trials

A listing of Saint-Quentin, France clinical trials actively recruiting patients volunteers.

RESULTS

Found (25) clinical trials

Safety and Efficacy of Modified Folfirinox Versus Gemcis in Bile Duct Tumours

At the same time as these results, triple therapies involving 5FU + oxiplatin + irinotecan have objectively shown a significant increase in overall survival of patients with metastatic pancreatic adenocarcinoma compared to gemcitabine alone (median of 11.1 months versus 6.8 months, HR = 0.57 [0.45 - 0.73] p < 0.0001). ...

Phase

0.0 miles

Learn More »

Study Evaluating Intervention in the Development of Clinical Research in Non-Academic Health Institution (ERNU)

French National recommendations ask to increase the accessibility of patients to clinical trials. But this accessibility is far from the optimal care in non-university healthcare institutions (public and private hospital). These non-academic healthcare facilities support at national level about 60% of chemotherapy and 70% of radiotherapy, but only 17% of ...

Phase N/A

0.0 miles

Learn More »

Randomised Study Evaluating Adjuvant Chemotherapy After Resection of Stage III Colonic Adenocarcinoma in Patients of 70 and Over

Colorectal cancer occurs mainly in elderly patients. Recent estimation showed that in France more than 50% of the patients diagnosed with a colorectal cancer are 70 years old or more. Adjuvant chemotherapy has demonstrated a benefit on disease-free survival and overall survival after a stage III colon cancer resection. Nevertheless ...

Phase

0.0 miles

Learn More »

A Randomized Phase III Trial Comparing Folfirinox to Gemcitabine in Locally Advanced Pancreatic Carcinoma

French national multicentric phase III trial evaluating chemotherapy with Folfirinox or gemcitabine in locally advanced pancreatic carcinoma

Phase

0.0 miles

Learn More »

Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLC

The purpose of this study is to find out whether it is better to receive a new drug, MEDI4736, or better to receive no further treatment after surgery (and possibly chemotherapy) for lung cancer.

Phase

0.0 miles

Learn More »

Role of Vitamin C at 6 Months on Incidence of Complex Regional Pain Syndrome Type I in Upper Limb Surgery

The preventive role of vitamin C on the development of CRPS type 1 was already demonstrated in traumatology and foot surgery. The management of CRPS type 1 is long and expensive. A preventive care seems beneficial. Some studies already performed suggest a similar role in scheduled surgery of the upper ...

Phase

0.0 miles

Learn More »

EPIPAGE2 Cohort Study Follow up at Five and a Half Years

Epipage 2 (epidemiologic study on small-for-gestational-age children) is a nationwide study implemented to improve our knowledge of the outcome of preterm children in France. This study was launched on March 28, 2011 and includes three groups of preterm children, all born before 35 weeks: extremely preterm infants (born between 22 ...

Phase N/A

0.0 miles

Learn More »

Combination of Cetuximab With Afatinib for Patient With EGFR Mutated Lung Cancer

Until recently, the first line treatment of metastatic Non Small Cell Lung Cancer (NSCLC) was a platine-based chemotherapy. It has been changed by the discovery of EGFR (Epidermal Growth Factor Receptor) mutations and associated treatment with Tyrosine Kinase Inhibitor (TKI) of EGFR. The superiority of EGFR TKI over chemotherapy for ...

Phase

0.0 miles

Learn More »

Association Between Cerebral Arterial Vascular Flow and Sleep Apnea in Neurodegenerative Alterations

Numerous studies pointed out the close relationship between sleep apnea and cognitive impairment. To the investigators' knowledge, no trials have assessed the existence of a relationship between the IAH index and the cerebral arterial blood flow rate (macrocirculation). Developments in magnetic resonance imaging (MRI) provide new insights into the quantitative ...

Phase N/A

0.0 miles

Learn More »

High Dose Therapy Followed by Autologous Transplantation for Myeloma Patients With Severe Renal Impairment

RI is associated with poor prognosis and short median survival (32 months vs 55 months for MM patients with normal renal function). Thus, RI remains a major challenge for hematologists, including decisions on optimal anti-myeloma therapy, potential dialysis, supportive care and quality of life. The combination of a proteasome inhibitor ...

Phase N/A

0.0 miles

Learn More »